SEATTLE, May 16, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced that the following presentations of data for L-BLP25 (formerly known as Stimuvax) and PX-866 will take place at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago:
Abstract #7500 START - A Phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. Charles A. Butts, MD, FRCPC Oral Abstract Session - Lung Cancer Tuesday, June 4 9:45 AM - 10:00 AM
Abstract #2053 Phase II study of PX-866 in recurrent glioblastoma. Marshall W. Pitz, MD, FRCPC General Poster Session - CNS tumors Saturday, June 1 8:00 AM - 11:45 AM
Abstract #5042 NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC). Sebastien J. Hotte, MD, MSc General Poster Session - Genitourinary Cancer Monday June 3 8:00 AM - 11:45 AML-BLP25 - In connection with the upcoming presentation, Oncothyreon today announced detailed results from the randomized Phase III START trial of the investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). The trial was conducted by Merck Serono, a division of Merck KGaA, Darmstadt, Germany, under a license agreement with Oncothyreon. The primary endpoint of improving overall survival (OS) was not met. In a predefined subgroup of patients receiving initial concurrent chemoradiotherapy (CRT), a combination of chemotherapy and radiotherapy given at the same time, a median overall survival of 30.8 months versus 20.6 months was observed based on a post hoc analysis in patients treated with L-BLP25 versus placebo respectively (HR 0.78, 95% CI 0.64-0.95, p=0.016, n=806). The START trial is assessing the safety, efficacy and tolerability of L-BLP25 in patients with unresectable, locally advanced Stage III NSCLC who have not progressed after initial CRT, which is the current standard of care. Before receiving treatment with either L-BLP25 or placebo in the START trial, two-thirds of patients had received concurrent CRT and one-third had received sequential CRT (radiotherapy started after completion of chemotherapy). The trial did not meet its primary objective of demonstrating a significantly improved OS with L-BLP25 compared to placebo in the primary analysis study population (n=1,239). Median OS was 25.6 months for patients in the L-BLP25 group compared with 22.3 months for those in the placebo group (adjusted HR 0.88, 95% CI 0.75-1.03, p=0.123). In a post hoc analysis of the predefined subgroup of patients receiving initial concurrent CRT (n=806), patients receiving L-BLP25 had a median OS of 30.8 months compared to patients receiving placebo, who had a median OS of 20.6 months [HR 0.78; 95% CI 0.64-0.95; p=0.016]). In patients receiving sequential CRT followed by L-BLP25 or placebo a median OS of 19.4 months was observed for the L-BLP25 group compared with 24.6 months for the placebo group (n=433; HR 1.12; 95% CI 0.87-1.44; p=0.38). Predefined subgroup analyses included, among others, disease stage (IIIA or IIIB), response to initial CRT (stable disease versus objective response), type of initial CRT (concurrent versus sequential) and geographic region.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts